| __timestamp | BioCryst Pharmaceuticals, Inc. | Catalent, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7461000 | 334800000 |
| Thursday, January 1, 2015 | 13047000 | 337300000 |
| Friday, January 1, 2016 | 11253000 | 358100000 |
| Sunday, January 1, 2017 | 13933000 | 402600000 |
| Monday, January 1, 2018 | 29514000 | 462600000 |
| Tuesday, January 1, 2019 | 37121000 | 512000000 |
| Wednesday, January 1, 2020 | 67929000 | 577900000 |
| Friday, January 1, 2021 | 118818000 | 687000000 |
| Saturday, January 1, 2022 | 159371000 | 844000000 |
| Sunday, January 1, 2023 | 213894000 | 831000000 |
| Monday, January 1, 2024 | 935000000 |
Infusing magic into the data realm
In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Over the past decade, Catalent, Inc. and BioCryst Pharmaceuticals, Inc. have demonstrated contrasting trajectories in their SG&A efficiency.
Catalent, Inc. has shown a steady increase in SG&A expenses, peaking at approximately $935 million in 2024, reflecting a growth of over 180% since 2014. This rise indicates a strategic investment in operational expansion and market penetration. In contrast, BioCryst Pharmaceuticals, Inc. has experienced a more volatile pattern, with expenses surging by nearly 280% from 2014 to 2023, reaching around $214 million. This fluctuation suggests a dynamic approach to scaling operations and adapting to market demands.
The data highlights the importance of strategic SG&A management in sustaining competitive advantage and driving growth in the pharmaceutical sector.
Bristol-Myers Squibb Company or Catalent, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Viatris Inc. and BioCryst Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Catalent, Inc. vs Cytokinetics, Incorporated
Catalent, Inc. or Ionis Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Catalent, Inc. or Perrigo Company plc
Selling, General, and Administrative Costs: Exelixis, Inc. vs BioCryst Pharmaceuticals, Inc.
Veracyte, Inc. or BioCryst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of ACADIA Pharmaceuticals Inc. and BioCryst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Arrowhead Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.
ImmunityBio, Inc. vs BioCryst Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Dynavax Technologies Corporation or BioCryst Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Travere Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.